Carlyle Group portfolio companies Sequent Scientific and Viyash Life Sciences are in advanced talks for a potential Rs 7,000-8,000 crore merger, according to people familiar with the matter. Boards of both companies are likely to discuss the possibility in the coming week, according to those cited. There is no certainty a transaction will materialise, they said.
Sequent is listed and Viyash isn't. Viyash generated 1.5 times the operating profits of Sequent in FY24, said the people quoted above, adding that the two are exploring the merger due to possible back-end synergies.
ET first reported the story online on Thursday.
Carlyle, Sequent and Viyash didn't respond to queries.
Manufacturing Capacity
Artificial Intelligence(AI)
Java Programming with ChatGPT: Learn using Generative AI
By — Metla Sudha Sekhar, Developer and Lead Instructor
Artificial Intelligence(AI)
Basics of Generative AI: Unveiling Tomorrow's Innovations
By — Metla Sudha Sekhar, Developer and Lead Instructor
Artificial Intelligence(AI)
Generative AI for Dynamic Java Web Applications with ChatGPT
By — Metla Sudha Sekhar, Developer and Lead Instructor
Artificial Intelligence(AI)
Mastering C++ Fundamentals with Generative AI: A Hands-On
By — Metla Sudha Sekhar, Developer and Lead Instructor
Artificial Intelligence(AI)
Master in Python Language Quickly Using the ChatGPT Open AI
By — Metla Sudha Sekhar, Developer and Lead Instructor
Office Productivity
Zero to Hero in Microsoft Excel: Complete Excel guide 2024
By — Metla Sudha Sekhar, Developer and Lead